HUE039353T2 - Anti-IL-17 ellenanyagok - Google Patents

Anti-IL-17 ellenanyagok

Info

Publication number: HUE039353T2
Authority: HU; Hungary
Prior art keywords: antibodies
Prior art date: 2005-12-13

Application number

HUE11192240A

Other languages

English (en)

Hungarian (hu)

Inventor

Barrett Allan

Chi-Kin Chow

Lihua Huang

Ling Liu

Jirong Lu

Kingman Ng

Jonathan Wendell Tetreault

Andrew Gordon Werner

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-13

Filing date

2006-12-05

Publication date

2018-12-28

2006-12-05 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2018-12-28 Publication of HUE039353T2 publication Critical patent/HUE039353T2/hu

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Mycology (AREA)
Pain & Pain Management (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

HUE11192240A 2005-12-13 2006-12-05 Anti-IL-17 ellenanyagok HUE039353T2 (hu)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US74995305P	2005-12-13	2005-12-13
US80194806P	2006-05-19	2006-05-19

Publications (1)

Publication Number	Publication Date
HUE039353T2 true HUE039353T2 (hu)	2018-12-28

Family

ID=38008638

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HUE11192240A HUE039353T2 (hu)	2005-12-13	2006-12-05	Anti-IL-17 ellenanyagok
HUS1600037C HUS1600037I1 (hu)	2005-12-13	2016-09-07	Anti-IL-17 ellenanyagok

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
HUS1600037C HUS1600037I1 (hu)	2005-12-13	2016-09-07	Anti-IL-17 ellenanyagok

Country Status (24)

Country	Link
US (2)	US7838638B2 (2)
EP (4)	EP2481753B1 (2)
JP (1)	JP5063612B2 (2)
KR (1)	KR101158959B1 (2)
CN (1)	CN101326195B9 (2)
AU (1)	AU2006325860B2 (2)
BE (1)	BE2016C045I2 (2)
BR (1)	BRPI0619792B1 (2)
CA (1)	CA2631938C (2)
CY (3)	CY1113097T1 (2)
DK (2)	DK1963368T6 (2)
EA (1)	EA014298B1 (2)
ES (2)	ES2672221T3 (2)
HR (2)	HRP20120606T4 (2)
HU (2)	HUE039353T2 (2)
IL (1)	IL191217A (2)
LT (2)	LT2481753T (2)
LU (1)	LU93189I2 (2)
NO (2)	NO340827B1 (2)
PL (2)	PL2481753T3 (2)
PT (2)	PT2481753T (2)
RS (2)	RS57255B1 (2)
SI (2)	SI1963368T1 (2)
WO (1)	WO2007070750A1 (2)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070269428A1 (en)	2003-11-21	2007-11-22	Celltech R&D Limited	Method for the Treatment of Multiple Sclerosis by Inhibiting Il-17 Activity
CN101326195B9 (zh) *	2005-12-13	2022-11-11	伊莱利利公司	抗il-17抗体
US7790163B2 (en)	2006-03-10	2010-09-07	Zymogenetics, Inc.	Antibodies that bind both IL-17A and IL-17F and methods of using the same
US7910703B2 (en)	2006-03-10	2011-03-22	Zymogenetics, Inc.	Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US20070218065A1 (en)	2006-03-10	2007-09-20	Jaspers Stephen R	Antibodies that bind both il-17a and il-17f and methods of using the same
TW200815469A (en)	2006-06-23	2008-04-01	Astrazeneca Ab	Compounds
GB0612928D0 (en) *	2006-06-29	2006-08-09	Ucb Sa	Biological products
CA2660463C (en)	2006-08-11	2013-07-16	Schering Corporation	Antibodies to il-17a
GB0620729D0 (en)	2006-10-18	2006-11-29	Ucb Sa	Biological products
IN2009DN05758A (2)	2007-03-12	2015-07-24	Esbatech Ag
KR101530723B1 (ko)	2007-06-25	2015-06-22	에스바테크 - 어 노바티스 컴파니 엘엘씨	단일 쇄 항체의 서열에 기초한 공학처리 및 최적화
US20090074780A1 (en) *	2007-06-25	2009-03-19	David Urech	Methods of modifying antibodies, and modified antibodies with improved functional properties
US20110300154A1 (en) *	2007-08-21	2011-12-08	Children's Medical Center Corporation	Treatment of airway hyperreactivity
WO2009082624A2 (en) *	2007-12-10	2009-07-02	Zymogenetics, Inc.	Antagonists of il-17a, il-17f, and il-23 and methods of using the same
GB0807413D0 (en)	2008-04-23	2008-05-28	Ucb Pharma Sa	Biological products
SG10201608871XA (en)	2008-05-05	2016-12-29	Novimmune Sa	Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
JP5581323B2 (ja) *	2008-09-29	2014-08-27	ロシュグリクアートアクチェンゲゼルシャフト	ヒトｉｌ１７に対する抗体およびその使用
AU2009314111A1 (en) *	2008-11-12	2010-05-20	Merck Sharp & Dohme Corp.	BetaGI-IgG intron for enhanced anti-IGF1 R expression
WO2010062857A1 (en)	2008-11-26	2010-06-03	Allergan, Inc.	Klk-13 antibody inhibitor for treating dry eye
WO2010062858A1 (en) *	2008-11-26	2010-06-03	Allergan, Inc.	Il-17 antibody inhibitor for treating dry eye
EP2403531A4 (en)	2009-03-05	2013-02-27	Abbott Lab	IL-17 BINDING PROTEINS
CA2759848C (en)	2009-05-05	2018-12-04	Novimmune S.A.	Anti-il-17f antibodies and methods of use thereof
WO2011053763A2 (en)	2009-10-30	2011-05-05	Centocor Ortho Biotech Inc.	Il-17a antagonists
JO3417B1 (ar)	2010-01-08	2019-10-20	Regeneron Pharma	الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
EP2552967A4 (en) *	2010-04-02	2014-10-08	Amunix Operating Inc	BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
EP2569335B1 (en) *	2010-05-14	2018-08-22	Orega Biotech	Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
BR112013002831A2 (pt) *	2010-08-05	2016-11-01	Anaptysbio Inc	anticorpos direcionados contra a il-17
TW201302793A (zh) *	2010-09-03	2013-01-16	Glaxo Group Ltd	新穎之抗原結合蛋白
PH12013500660B1 (en) *	2010-10-08	2017-10-27	Novartis Ag	Methods of treating psoriasis using il-17 antagonists
GB201100282D0 (en)	2011-01-07	2011-02-23	Ucb Pharma Sa	Biological methods
US10208349B2 (en)	2011-01-07	2019-02-19	Ucb Biopharma Sprl	Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
SG10201510762YA (en)	2011-01-14	2016-01-28	Ucb Pharma Sa	Antibody molecules which bind il-17a and il-17f
TWI589299B (zh)	2011-10-11	2017-07-01	再生元醫藥公司	用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en)	2011-10-11	2018-04-17	Sanofi Biotechnology	Methods for the treatment of rheumatoid arthritis
CA2856252A1 (en)	2011-11-21	2013-05-30	Novartis Ag	Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non-response alleles
US9284283B2 (en)	2012-02-02	2016-03-15	Ensemble Therapeutics Corporation	Macrocyclic compounds for modulating IL-17
AU2013230490B2 (en)	2012-03-07	2017-04-13	Eli Lilly And Company	IL-17 antibody formulation
EP2838560A2 (en)	2012-04-20	2015-02-25	Novartis AG	Methods of treating ankylosing spondylitis using il-17 antagonists
AR090626A1 (es)	2012-04-20	2014-11-26	Lilly Co Eli	Anticuerpos anti-baff-anti-il-17 biespecificos
US8945553B2 (en) *	2012-05-22	2015-02-03	Bristol-Myers Squibb Company	Bispecific antibodies to IL-23 and IL-17A/F
US9676847B2 (en)	2012-06-25	2017-06-13	Orega Biotech	IL-17 antagonist antibodies
WO2014066726A2 (en)	2012-10-26	2014-05-01	Ensemble Therapeutics Corporation	Compounds for modulating il-17
HK1215174A1 (zh) *	2012-11-29	2016-08-19	Bayer Healthcare Llc	針對活化蛋白c的人源化單克隆抗體及其用途
LT2953969T (lt) *	2013-02-08	2019-12-10	Novartis Ag	Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
TW201444867A (zh)	2013-03-08	2014-12-01	Lilly Co Eli	抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體
WO2014155278A2 (en)	2013-03-26	2014-10-02	Novartis Ag	Methods of treating autoimmune diseases using il-17 antagonists
US9700485B2 (en)	2013-04-24	2017-07-11	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US20150004133A1 (en) *	2013-06-07	2015-01-01	The Regents Of The University Of California	Compositions And Methods For Treating Steatohepatitis, Liver Fibrosis, and Hepatocellular Carcinoma (HCC)
US9603882B2 (en)	2013-08-13	2017-03-28	Industrial Technology Research Institute	Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
EP4223312A1 (en)	2013-08-15	2023-08-09	Novartis AG	Methods of treating plaque psoriasis using il-17 antagonists
CA2929662C (en)	2013-11-18	2023-05-02	Shanghai Hengrui Pharmaceutical Co., Ltd.	Il-17a binding agent and uses thereof
WO2015099167A1 (ja) *	2013-12-27	2015-07-02	国立大学法人大阪大学	Ｉｌ－１７ａを標的とするワクチン
BR112016015140A2 (pt)	2013-12-30	2018-01-23	Epimab Biotherapeutics Inc.	imunoglobulina com fabs in-tandem e usos das mesmas
JP2017507939A (ja)	2014-02-21	2017-03-23	ジェネンテック，インコーポレイテッド	抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用
RU2577228C2 (ru) *	2014-03-14	2016-03-10	Закрытое Акционерное Общество "Биокад"	Анти-il-17-антитела, способ их получения и способ применения
TWI713453B (zh)	2014-06-23	2020-12-21	美商健生生物科技公司	干擾素α及ω抗體拮抗劑
MX2017003216A (es)	2014-09-10	2017-05-23	Novartis Ag	Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TWI716362B (zh)	2014-10-14	2021-01-21	瑞士商諾華公司	針對ｐｄ－ｌ１之抗體分子及其用途
AR103173A1 (es)	2014-12-22	2017-04-19	Novarits Ag	Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CN108064235A (zh)	2015-01-12	2018-05-22	阿菲博迪公司	Il-17a结合多肽
WO2016123329A2 (en)	2015-01-28	2016-08-04	Genentech, Inc.	Gene expression markers and treatment of multiple sclerosis
CN106336459B (zh) *	2015-07-13	2020-12-08	三生国健药业（上海）股份有限公司	抗人白细胞介素-17a单克隆抗体、其制备方法和应用
BR112017025264A2 (pt)	2015-07-16	2018-08-07	Lilly Co Eli	tratamento de prurido
EP3878465A1 (en)	2015-07-29	2021-09-15	Novartis AG	Combination therapies comprising antibody molecules to tim-3
US20180222982A1 (en)	2015-07-29	2018-08-09	Novartis Ag	Combination therapies comprising antibody molecules to pd-1
DK3317301T3 (da)	2015-07-29	2021-06-28	Immutep Sas	Kombinationsterapier omfattende antistofmolekyler mod lag-3
US11077187B2 (en)	2015-11-17	2021-08-03	Oklahoma Medical Research Foundation	Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
WO2017106656A1 (en)	2015-12-17	2017-06-22	Novartis Ag	Antibody molecules to pd-1 and uses thereof
RU2767329C2 (ru)	2016-02-06	2022-03-17	Эпимаб Биотерапьютикс, Инк.	Иммуноглобулин с тандемными fab-фрагментами и варианты его применения
CN107488227A (zh) *	2016-06-12	2017-12-19	三生国健药业（上海）股份有限公司	抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
WO2017221174A1 (en)	2016-06-22	2017-12-28	Novartis Ag	Methods of treating vitiligo using interleukin-17 (il-17) antibodies
WO2018015880A1 (en)	2016-07-19	2018-01-25	Novartis Ag	Methods of treating new-onset plaque type psoriasis using il-17 antagonists
KR102329490B1 (ko) *	2016-09-14	2021-11-23	베이징 한미 파마슈티컬 컴퍼니 리미티드	Ｉｌ-１７ａ에 특이적으로 결합하는 항체 및 그의 기능성 단편
JP2019505516A (ja)	2016-11-28	2019-02-28	ノバルティスアーゲー	インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
PE20191548A1 (es)	2017-02-10	2019-10-24	Genentech Inc	Anticuerpos contra triptasa, composiciones de estos y usos de estos
WO2018158741A1 (en)	2017-03-03	2018-09-07	Novartis Ag	Psoriasis disease modification following long-term treatment with an il-17 antagonist
CN110582512B (zh)	2017-03-10	2022-08-30	苏州鑫康合生物医药科技有限公司	针对il-17a和il-17f二者的单克隆抗体及其用途
US10941178B2 (en) *	2017-03-17	2021-03-09	Gilead Sciences, Inc.	Method of purifying an antibody
US10676522B2 (en)	2017-05-05	2020-06-09	Novartis Ag	Methods of selectively treating asthma using IL-17 antagonists
CA3065553A1 (en)	2017-06-18	2018-12-27	Kindred Biosciences, Inc.	Il17a antibodies and antagonists for veterinary use
WO2019027828A1 (en)	2017-08-04	2019-02-07	Eli Lilly And Company	DOSAGE SCHEME OF ANTI-IL-17 ANTIBODIES
EP3672988A1 (en)	2017-08-23	2020-07-01	Eli Lilly and Company	Treatment of genital psoriasis
WO2019087133A1 (en)	2017-11-02	2019-05-09	Novartis Ag	Method of treating tendinopathy using interleukin-17 (il-17)
WO2019091449A1 (zh) *	2017-11-10	2019-05-16	江苏恒瑞医药股份有限公司	Cd96抗体、其抗原结合片段及医药用途
KR102048475B1 (ko) *	2017-11-10	2019-11-26	주식회사 와이바이오로직스	IL-17A (Interleukin-17A)에 특이적으로 결합하는 항체 및 이의 용도
US20200277369A1 (en)	2017-11-20	2020-09-03	Novartis Ag	Method of treating hidradentitis suppurativa with il-17 antagonists
BR112020010579A2 (pt)	2017-11-30	2020-11-10	Novartis Ag	receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo
US11619832B2 (en)	2018-03-08	2023-04-04	Coopervision International Limited	Identification of contact lens wearers predisposed to contact lens discomfort
MX2020011588A (es)	2018-05-03	2020-12-07	Shanghai Epimab Biotherapeutics Co Ltd	Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas.
US12110323B2 (en)	2018-05-17	2024-10-08	Jiangsu Qyuns Therapeutics Co., Ltd.	Anti-human interleukin 17A monoclonal antibody and application thereof
UY38251A (es)	2018-06-01	2019-12-31	Novartis Ag	Moléculas de unión contra bcma y usos de las mismas
GB201810327D0 (en)	2018-06-22	2018-08-08	Bicycletx Ltd	Peptide ligands for binding to IL-17
AU2019329958B2 (en)	2018-08-29	2025-05-29	Regeneron Pharmaceuticals, Inc.	Methods and compositions for treating subjects having rheumatoid arthritis
US12473357B2 (en)	2018-09-25	2025-11-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of antagonists of Th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
CN111018974B (zh) *	2018-10-10	2022-04-01	东莞市朋志生物科技有限公司	一种抗人心肌肌钙蛋白i的重组抗体
GB201820316D0 (en)	2018-12-13	2019-01-30	Bicyclerd Ltd	Bicyclic peptide ligands specific for IL-17
CN109369806B (zh) *	2019-01-14	2019-04-19	迈威(上海)生物科技有限公司	苏金单抗制品中半胱氨酸化变异体的去除方法
JP7525499B2 (ja)	2019-01-31	2024-07-30	ヌマブセラピューティクスアクチェンゲゼルシャフト	ＴＮＦα及びＩＬ－１７Ａに対する特異性を有する多重特異性抗体、ＩＬ－１７Ａを標的とする抗体、及びそれらの使用方法
EP3689907A1 (en)	2019-01-31	2020-08-05	Numab Therapeutics AG	Antibodies targeting il-17a and methods of use thereof
BR112021014377A2 (pt)	2019-01-31	2021-12-28	Regeneron Pharma	Composições e métodos para o tratamento de artrite idiopática juvenil
KR102735988B1 (ko)	2019-02-18	2024-12-03	일라이 릴리 앤드 캄파니	치료 항체 제제
AU2020261431A1 (en)	2019-04-24	2021-12-09	Regeneron Pharmaceuticals, Inc.	Methods of diagnosis and treatment of rheumatoid arthritis
KR102400401B1 (ko) *	2019-05-22	2022-05-24	(주)셀인바이오	항염증 펩타이드 및 항염증 조성물
EP3980459A1 (en)	2019-06-04	2022-04-13	Sanofi Biotechnology	Compositions and methods for treating pain in subj ects with rheumatoid arthritis
MY205369A (en)	2019-07-26	2024-10-17	Sinocelltech Ltd	Humanized anti-il17a antibody and use thereof
EP4006053A4 (en)	2019-07-30	2022-10-26	Jiangsu Hengrui Medicine Co., Ltd.	METHOD OF TREATMENT OF AUTOIMMUNE DISEASE BY IL-17 ANTAGONISTS
US12497449B2 (en)	2019-09-20	2025-12-16	Novartis Ag	Methods of treating autoimmune diseases using interleukin-17 (IL-17) antagonists
EP4045641A1 (en)	2019-10-15	2022-08-24	Eli Lilly and Company	Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
AU2020386669A1 (en)	2019-11-19	2022-06-02	Novartis Ag	Methods of treating Lupus Nephritis using interleukin-17 (IL-17) antagonists
EP4069737A2 (en)	2019-12-06	2022-10-12	Novartis AG	Methods of treating lichen planus using interleukin-17 (il-17) antagonists
GB201918558D0 (en)	2019-12-16	2020-01-29	Bicycle Tx Ltd	Bicyclic peptide ligands specific for IL-17
WO2021123767A1 (en)	2019-12-16	2021-06-24	Bicycletx Limited	Bicyclic peptide ligands specific for il-17
GB201918559D0 (en)	2019-12-16	2020-01-29	Bicycle Tx Ltd	Bicyclic peptide ligands specific for IL-17
GB201918557D0 (en)	2019-12-16	2020-01-29	Bicycle Tx Ltd	Bicyclic peptide ligands specific for IL-17
GB201919062D0 (en) *	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Antibody
MX2022014925A (es)	2020-05-27	2023-01-04	Sanofi Sa	Moduladores de il-17a.
US20230286943A1 (en)	2020-05-27	2023-09-14	Sanofi	Il-17a modulators
BR112022026273A2 (pt)	2020-06-23	2023-01-17	Novartis Ag	Métodos de tratamento da doença ocular da tireoide e orbitopatia de graves usando antagonistas de interleucina-17 (il-17)
US20240025993A1 (en)	2020-11-06	2024-01-25	Novartis Ag	Cd19 binding molecules and uses thereof
CN115746132B (zh) *	2021-09-03	2023-09-08	三优生物医药(上海)有限公司	抗il-17a抗体及其用途
IT202100023816A1 (it) *	2021-09-16	2023-03-16	Takis S R L	Anticorpo contro SARS-CoV-2 e suoi usi in campo medico.
CN113896793B (zh) *	2021-09-30	2023-05-26	港科鹏禾生物(苏州)有限公司	一种抗人il-17rc的单克隆抗体及其应用
CA3253618A1 (en)	2022-05-16	2023-11-23	Novartis Ag	METHODS FOR TREATMENT OF GIANT CELL ARTERITIS USING INTERLEUKIN-17 (IL-17) ANTAGONISTS
EP4525914A1 (en)	2022-05-18	2025-03-26	Novartis AG	Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists
KR20250117693A (ko)	2022-12-09	2025-08-05	사노피	치료용 화합물
WO2025083549A1 (en)	2023-10-16	2025-04-24	Sun Pharma Advanced Research Company Limited	Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders
WO2025104230A1 (en)	2023-11-17	2025-05-22	Sanofi	Benzoxazoles as modulators of il-17a
WO2025248073A1 (en)	2024-05-30	2025-12-04	Sanofi	Therapeutic compounds
KR20250179689A (ko)	2024-06-20	2025-12-30	(주)셀트리온	안정한 약제학적 제제
CN120249218B (zh) *	2024-10-15	2026-03-20	武汉纺织大学	一种分泌抗微纳塑料广谱性单克隆抗体的杂交瘤细胞株及其应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5225A (en)		1847-08-07		Latch
US539A (en)		1837-12-26		Standard measurer for taking measure for coats
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE300615T1 (de)	1990-08-29	2005-08-15	Genpharm Int	Transgene mäuse fähig zur produktion heterologer antikörper
ATE352612T1 (de)	1990-08-29	2007-02-15	Pharming Intellectual Pty Bv	Homologe rekombination in säugetier-zellen
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US6284471B1 (en)	1991-03-18	2001-09-04	New York University Medical Center	Anti-TNFa antibodies and assays employing anti-TNFa antibodies
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
WO1993004169A1 (en)	1991-08-20	1993-03-04	Genpharm International, Inc.	Gene targeting in animal cells using isogenic dna constructs
ATE244763T1 (de)	1992-02-11	2003-07-15	Cell Genesys Inc	Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US6562333B1 (en)	1993-06-14	2003-05-13	Schering Corporation	Purified mammalian CTLA-8 antigens and related reagents
US6274711B1 (en) *	1993-06-14	2001-08-14	Inserm, Institut National De La Sante Et De La Recherche Medicale	Purified mammalian CTLA-8 antigens and related reagents
US5625825A (en)	1993-10-21	1997-04-29	Lsi Logic Corporation	Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5698762A (en)	1994-12-09	1997-12-16	Dauerman; Leonard	Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
WO1997007671A1 (en)	1995-08-29	1997-03-06	Kirin Beer Kabushiki Kaisha	Chimeric animal and method for constructing the same
GB0312481D0 (en) *	2003-05-30	2003-07-09	Celltech R&D Ltd	Antibodies
EP1644416A4 (en)	2003-06-30	2007-08-29	Centocor Inc	ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
US20070269428A1 (en)	2003-11-21	2007-11-22	Celltech R&D Limited	Method for the Treatment of Multiple Sclerosis by Inhibiting Il-17 Activity
GB0417487D0 (en) *	2004-08-05	2004-09-08	Novartis Ag	Organic compound
GB0425569D0 (en) *	2004-11-19	2004-12-22	Celltech R&D Ltd	Biological products
CN101326195B9 (zh) *	2005-12-13	2022-11-11	伊莱利利公司	抗il-17抗体

2006
- 2006-12-05 CN CN200680046605.8A patent/CN101326195B9/zh active Active
- 2006-12-05 US US12/095,398 patent/US7838638B2/en active Active
- 2006-12-05 HU HUE11192240A patent/HUE039353T2/hu unknown
- 2006-12-05 LT LTEP11192240.7T patent/LT2481753T/lt unknown
- 2006-12-05 BR BRPI0619792-2A patent/BRPI0619792B1/pt active IP Right Grant
- 2006-12-05 WO PCT/US2006/061586 patent/WO2007070750A1/en not_active Ceased
- 2006-12-05 EP EP11192240.7A patent/EP2481753B1/en active Active
- 2006-12-05 AU AU2006325860A patent/AU2006325860B2/en active Active
- 2006-12-05 EP EP20190492.7A patent/EP3808769A1/en active Pending
- 2006-12-05 KR KR1020087014147A patent/KR101158959B1/ko active Active
- 2006-12-05 PL PL11192240T patent/PL2481753T3/pl unknown
- 2006-12-05 PT PT111922407T patent/PT2481753T/pt unknown
- 2006-12-05 PT PT06846464T patent/PT1963368E/pt unknown
- 2006-12-05 SI SI200631427T patent/SI1963368T1/sl unknown
- 2006-12-05 RS RS20180601A patent/RS57255B1/sr unknown
- 2006-12-05 ES ES11192240.7T patent/ES2672221T3/es active Active
- 2006-12-05 DK DK06846464.3T patent/DK1963368T6/da active
- 2006-12-05 RS RS20120418A patent/RS52509B2/sr unknown
- 2006-12-05 DK DK11192240.7T patent/DK2481753T3/en active
- 2006-12-05 CA CA2631938A patent/CA2631938C/en active Active
- 2006-12-05 ES ES06846464T patent/ES2389780T7/es active Active
- 2006-12-05 EP EP06846464.3A patent/EP1963368B3/en active Active
- 2006-12-05 PL PL06846464T patent/PL1963368T6/pl unknown
- 2006-12-05 EA EA200870050A patent/EA014298B1/ru active Protection Beyond IP Right Term
- 2006-12-05 HR HRP20120606TT patent/HRP20120606T4/hr unknown
- 2006-12-05 EP EP18160779.7A patent/EP3366702B1/en active Active
- 2006-12-05 JP JP2008545908A patent/JP5063612B2/ja active Active
- 2006-12-05 SI SI200632258T patent/SI2481753T1/en unknown
2008
- 2008-05-01 IL IL191217A patent/IL191217A/en active Protection Beyond IP Right Term
- 2008-06-26 NO NO20082905A patent/NO340827B1/no active Protection Beyond IP Right Term
2010
- 2010-10-21 US US12/908,892 patent/US8110191B2/en active Active
2012
- 2012-09-07 CY CY20121100807T patent/CY1113097T1/el unknown
2016
- 2016-08-24 CY CY2016030C patent/CY2016030I1/el unknown
- 2016-08-25 LT LTPA2016026C patent/LTC1963368I2/lt unknown
- 2016-08-31 BE BE2016C045C patent/BE2016C045I2/fr unknown
- 2016-08-31 LU LU93189C patent/LU93189I2/fr unknown
- 2016-09-07 HU HUS1600037C patent/HUS1600037I1/hu unknown
2017
- 2017-08-18 NO NO2017044C patent/NO2017044I2/no unknown
2018
- 2018-06-15 HR HRP20180941TT patent/HRP20180941T1/hr unknown
- 2018-06-27 CY CY20181100670T patent/CY1120365T1/el unknown

Also Published As

Publication number	Publication date
ES2672221T3 (es)	2018-06-13
ES2389780T3 (es)	2012-10-31
RS57255B1 (sr)	2018-08-31
EP3366702B1 (en)	2023-08-09
HK1120275A1 (en)	2009-03-27
RS52509B (sr)	2013-04-30
HUS1600037I1 (hu)	2016-10-28
EP2481753B1 (en)	2018-04-18
DK1963368T6 (da)	2020-06-29
NO340827B1 (no)	2017-06-26
JP2009519348A (ja)	2009-05-14
PT2481753T (pt)	2018-07-13
CY1120365T1 (el)	2019-07-10
SI1963368T1 (sl)	2012-11-30
EP3366702A1 (en)	2018-08-29
CY1113097T1 (el)	2016-04-13
JP5063612B2 (ja)	2012-10-31
EP3808769A1 (en)	2021-04-21
LU93189I2 (fr)	2016-10-31
EA200870050A1 (ru)	2009-12-30
EP1963368A1 (en)	2008-09-03
HRP20120606T1 (en)	2012-10-31
BRPI0619792A2 (pt)	2011-10-18
EA014298B1 (ru)	2010-10-29
SI2481753T1 (en)	2018-06-29
AU2006325860A1 (en)	2007-06-21
LTPA2016026I1 (lt)	2016-09-26
CA2631938C (en)	2014-05-20
ES2389780T7 (es)	2021-01-14
EP2481753A1 (en)	2012-08-01
EP1963368B1 (en)	2012-07-18
NO2017044I1 (no)	2017-08-18
PT1963368E (pt)	2012-09-14
WO2007070750A1 (en)	2007-06-21
US20110027290A1 (en)	2011-02-03
RS52509B2 (sr)	2020-09-30
BE2016C045I2 (2)	2026-02-02
AU2006325860B2 (en)	2011-09-22
NO2017044I2 (no)	2017-08-18
CN101326195B9 (zh)	2022-11-11
DK1963368T3 (da)	2012-08-06
LT2481753T (lt)	2018-05-25
CY2016030I2 (el)	2016-12-14
PL1963368T3 (pl)	2012-11-30
LTC1963368I2 (lt)	2018-01-10
CY2016030I1 (el)	2016-12-14
CN101326195B (zh)	2012-01-11
PL1963368T6 (pl)	2021-02-08
DK2481753T3 (en)	2018-06-18
CN101326195A (zh)	2008-12-17
US20080269467A1 (en)	2008-10-30
PL2481753T3 (pl)	2018-09-28
CA2631938A1 (en)	2007-06-21
KR101158959B1 (ko)	2012-07-09
IL191217A (en)	2015-10-29
HRP20120606T4 (hr)	2020-08-07
BRPI0619792B1 (pt)	2021-09-28
US8110191B2 (en)	2012-02-07
NO20082905L (no)	2008-09-03
US7838638B2 (en)	2010-11-23
EP1963368B3 (en)	2020-06-10
KR20080068122A (ko)	2008-07-22
HRP20180941T1 (hr)	2018-08-10

Publication	Publication Date	Title
HUS1600037I1 (hu)	2016-10-28	Anti-IL-17 ellenanyagok
FIC20230027I1 (fi)	2023-08-02	Tremelimumabi
HUS2100053I1 (hu)	2021-12-28	Interleukin-13-antitest-készítmény
LTPA2019520I1 (lt)	2019-11-11	Rekombinantiniai anti-IL-23 antikūnai
CY2018027I2 (el)	2020-05-29	Ανταγωνιστικα αντισωματα il-17
HRP20150176T1 (xx)	2015-03-27	Protutijela protiv miostatina
NO20076607L (no)	2008-02-27	TWEAK - bindende antistoff
DK1964852T3 (da)	2013-07-08	Anti-ilt7-antistof
NO20071430L (no)	2007-05-15	Anti-OX4OL antistoffer
ATE483732T1 (de)	2010-10-15	Madcam-antikörper
PT1920065T (pt)	2018-12-04	Anticorpos anti-alfavbeta6 e suas utilizações
DK1737891T3 (da)	2013-03-25	Anti-p-selectin-antistoffer
PL2177537T3 (pl)	2012-06-29	Przeciwciała przeciw MadCAM
DK1853310T3 (da)	2012-10-22	Anti-Abeta-antistofpræparat
EP1853313A4 (en)	2009-07-29	HUMANIZED L243 ANTIBODIES
DK1907748T3 (da)	2014-06-10	Rørforbindelse
DE602006012066D1 (de)	2010-03-18	Daraus
DE502006001178D1 (de)	2008-09-04	Pipettiervorrichtung
DE502005005547D1 (de)	2008-11-13	Pipettiervorrichtung
DE502006008367D1 (de)	2011-01-05	Pipettiervorrichtung
PL1871804T3 (pl)	2014-01-31	Przeciwciała wiążące CCX-CKR2
DE112006003220A5 (de)	2008-09-18	Ventilblock
DE602006015023D1 (de)	2010-08-05	Vergaser
IS8562A (is)	2006-10-30	Ónæmisglóbúlín
FI20055336L (fi)	2006-12-23	Kuristin